<DOC>
	<DOC>NCT00757029</DOC>
	<brief_summary>The noradrenergic system plays a known role in attentional systems and suspected causal role in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as a inhibitor of norepinephrine transporter(SLC6A2). The investigators hypothesis is that norepinephrine transporter polymorphism is associated with responses and adverse effects of OROS-methylphenidate in treatment of ADHD.</brief_summary>
	<brief_title>Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>ADHD Physically healthy Neurological illness Concurrent additional psychiatric treatment &lt; IQ 70 Psychotic disorder Major mood disorder needed other psychiatric medication Significant suicidal ideation Pervasive developmental disorder</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>ADHD,</keyword>
	<keyword>norepinephrine transporter</keyword>
	<keyword>pharmacogenetics</keyword>
</DOC>